Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA35920
Max Phase: Preclinical
Molecular Formula: C12H13NO4S
Molecular Weight: 267.31
Molecule Type: Small molecule
Associated Items:
ID: ALA35920
Max Phase: Preclinical
Molecular Formula: C12H13NO4S
Molecular Weight: 267.31
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: COc1ccc(C2=N[C@@](C)(C(=O)O)CS2)c(O)c1
Standard InChI: InChI=1S/C12H13NO4S/c1-12(11(15)16)6-18-10(13-12)8-4-3-7(17-2)5-9(8)14/h3-5,14H,6H2,1-2H3,(H,15,16)/t12-/m1/s1
Standard InChI Key: QXLSXGGAQGTCSP-GFCCVEGCSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 267.31 | Molecular Weight (Monoisotopic): 267.0565 | AlogP: 1.74 | #Rotatable Bonds: 3 |
Polar Surface Area: 79.12 | Molecular Species: ACID | HBA: 5 | HBD: 2 |
#RO5 Violations: 0 | HBA (Lipinski): 5 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 3.08 | CX Basic pKa: 0.58 | CX LogP: 2.65 | CX LogD: -0.82 |
Aromatic Rings: 1 | Heavy Atoms: 18 | QED Weighted: 0.87 | Np Likeness Score: 0.58 |
1. Bergeron RJ, Wiegand J, McManis JS, Bussenius J, Smith RE, Weimar WR.. (2003) Methoxylation of desazadesferrithiocin analogues: enhanced iron clearing efficiency., 46 (8): [PMID:12672247] [10.1021/jm020412d] |
2. Bergeron RJ, Wiegand J, McManis JS, Weimar WR, Park JH, Eiler-McManis E, Bergeron J, Brittenham GM.. (2005) Partition-variant desferrithiocin analogues: organ targeting and increased iron clearance., 48 (3): [PMID:15689166] [10.1021/jm049306x] |
3. Bergeron RJ, Wiegand J, McManis JS, Vinson JR, Yao H, Bharti N, Rocca JR.. (2006) (S)-4,5-dihydro-2-(2-hydroxy-4-hydroxyphenyl)-4-methyl-4-thiazolecarboxylic acid polyethers: a solution to nephrotoxicity., 49 (9): [PMID:16640338] [10.1021/jm0508944] |
4. Bergeron RJ, Wiegand J, McManis JS, Bharti N.. (2006) The design, synthesis, and evaluation of organ-specific iron chelators., 49 (24): [PMID:17125256] [10.1021/jm0608816] |
5. Bergeron RJ, Bharti N, McManis JS, Wiegand J.. (2015) Metabolically programmed iron chelators., 23 (17): [PMID:26231739] [10.1016/j.bmc.2015.06.059] |
Source(1):